My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
Our research aims to understand the epigenetic regulation of transposable elements and how their dysregulation contributes to the generation and development of cancer. In particular, we investigate their roles as gene regulators and triggers of anti-tumour immunity in blood cancers.
My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
The central aim of our laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient leukaemia therapies. We also focus on understanding haematopoietic stem cell biology with the hope to harness this knowledge for expanding them for therapeutic purposes.
My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the pathogenesis of B cell lymphoma and leukaemia.
I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
We are interested in understanding the cellular and molecular mechanisms responsible for relapses in acute lymphoblastic leukaemia and progressing these insights into translational diagnostics and clinical trials.
My work is currently focused on lymphoma, working on variant calling and gene expression analysis of NGS data.
My work is based on studying signalling networks in AML primary samples in order to predict responses to kinase inhibitors.
My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.
I am interested in unveiling and modelling the mechanisms that drive clonal haematopoiesis and exploring niche-based therapies to prevent it, as clonal haematopoiesis has been recently linked to an increase in the development of leukaemia and cardiovascular conditions.
My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
My work is focused on exploiting cell cycle vulnerabilities in tumour cells, particularly the role of MASTL or Greatwall kinase in cell cycle control. My research will explore the role of MASTL in AML and whether it could be a new therapeutic target in this disease.
We use novel mass cytometry technology following allogeneic haematopoietic stem-cell transplantation in patients, to define the global landscape of immune-cell populations preceding development of acute graft-versus-host disease (aGvHD) and to identify a dominant immunoregulatory role for subsets of CD56hi NK cells in limiting alloreative T-cell expansion and aGvHD.
My research project aims to identify germline mutations in families with leukaemia of unknown aetiology and study the intra and inter leukaemia heterogeneity observed in these families, through examination of clonal evolution and secondary genetic events.
Our research is focused in defining the cellular interactome of haematopoietic stem cells and leukaemic stem cells inside their niches during adulthood, ageing and disease. We are also interested in the cellular and molecular mechanisms that drive clonal selection and evolution in clonal haematopoiesis.
My research focusses on understanding cancer-specific metabolism in acute myeloid leukaemia and targeting this metabolism to overcome therapeutic resistance. I also explore the role of diet and obesity in leukaemogenesis and response to therapy.